Prolongation of cardiac graft survival with anti-CD4Ig plus HCTLA4Ig in primates

N. R. Krieger, D. Yuh, R. C. Robbins, C. G. Fathman

Research output: Contribution to journalArticle

Abstract

The aim of this study was to determine whether the use of combined immunotherapy with a brief course of anti-CD4-Ig and hCTLA4-Ig would prolong heterotopic cardiac allograft survival in primates. This model was based on our previous study of ôhigh responderö rats where a brief course of depletive anti-CD4 mAb plus hCTLA4-Ig successfully induced tolerance. Heterotopic cardiac transplants were performed in MLR mismatched rhesus recipients. A recently developed humanized anti-CD4 mAb, was given at a dose of 20 mg/kg iv on days -3, -2, -1, and 0. hCTLA4-Ig was given at 6 mg/kg iv on days 0 and 2 for the first recipient, and days 0, 2, 4, and 6 for the second recipient. No further immunoBuppression was given. The treated (n=2) or untreated (n=5) recipients were followed for graft function by daily palpation. Treatment with anti-CD4-Ig plus hCTLA4-Ig resulted in a significant prolongation of heart graft survival (42 days for the first recipient and 52 days for the second recipient) compared to untreated recipients (7 days). FACS analysis demonstrated CD4 depletion of treated animals to

Original languageEnglish (US)
JournalFASEB Journal
Volume12
Issue number5
StatePublished - Mar 20 1998
Externally publishedYes

Fingerprint

heart transplant
allografting
immunotherapy
Graft Survival
Grafts
Primates
heart
Transplants
Palpation
rats
dosage
Immunotherapy
Allografts
Rats
animals
Animals
Therapeutics

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Krieger, N. R., Yuh, D., Robbins, R. C., & Fathman, C. G. (1998). Prolongation of cardiac graft survival with anti-CD4Ig plus HCTLA4Ig in primates. FASEB Journal, 12(5).

Prolongation of cardiac graft survival with anti-CD4Ig plus HCTLA4Ig in primates. / Krieger, N. R.; Yuh, D.; Robbins, R. C.; Fathman, C. G.

In: FASEB Journal, Vol. 12, No. 5, 20.03.1998.

Research output: Contribution to journalArticle

Krieger, NR, Yuh, D, Robbins, RC & Fathman, CG 1998, 'Prolongation of cardiac graft survival with anti-CD4Ig plus HCTLA4Ig in primates', FASEB Journal, vol. 12, no. 5.
Krieger NR, Yuh D, Robbins RC, Fathman CG. Prolongation of cardiac graft survival with anti-CD4Ig plus HCTLA4Ig in primates. FASEB Journal. 1998 Mar 20;12(5).
Krieger, N. R. ; Yuh, D. ; Robbins, R. C. ; Fathman, C. G. / Prolongation of cardiac graft survival with anti-CD4Ig plus HCTLA4Ig in primates. In: FASEB Journal. 1998 ; Vol. 12, No. 5.
@article{8e3940130e3444f5879d470d0c0022ac,
title = "Prolongation of cardiac graft survival with anti-CD4Ig plus HCTLA4Ig in primates",
abstract = "The aim of this study was to determine whether the use of combined immunotherapy with a brief course of anti-CD4-Ig and hCTLA4-Ig would prolong heterotopic cardiac allograft survival in primates. This model was based on our previous study of {\^o}high responder{\"o} rats where a brief course of depletive anti-CD4 mAb plus hCTLA4-Ig successfully induced tolerance. Heterotopic cardiac transplants were performed in MLR mismatched rhesus recipients. A recently developed humanized anti-CD4 mAb, was given at a dose of 20 mg/kg iv on days -3, -2, -1, and 0. hCTLA4-Ig was given at 6 mg/kg iv on days 0 and 2 for the first recipient, and days 0, 2, 4, and 6 for the second recipient. No further immunoBuppression was given. The treated (n=2) or untreated (n=5) recipients were followed for graft function by daily palpation. Treatment with anti-CD4-Ig plus hCTLA4-Ig resulted in a significant prolongation of heart graft survival (42 days for the first recipient and 52 days for the second recipient) compared to untreated recipients (7 days). FACS analysis demonstrated CD4 depletion of treated animals to",
author = "Krieger, {N. R.} and D. Yuh and Robbins, {R. C.} and Fathman, {C. G.}",
year = "1998",
month = "3",
day = "20",
language = "English (US)",
volume = "12",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "5",

}

TY - JOUR

T1 - Prolongation of cardiac graft survival with anti-CD4Ig plus HCTLA4Ig in primates

AU - Krieger, N. R.

AU - Yuh, D.

AU - Robbins, R. C.

AU - Fathman, C. G.

PY - 1998/3/20

Y1 - 1998/3/20

N2 - The aim of this study was to determine whether the use of combined immunotherapy with a brief course of anti-CD4-Ig and hCTLA4-Ig would prolong heterotopic cardiac allograft survival in primates. This model was based on our previous study of ôhigh responderö rats where a brief course of depletive anti-CD4 mAb plus hCTLA4-Ig successfully induced tolerance. Heterotopic cardiac transplants were performed in MLR mismatched rhesus recipients. A recently developed humanized anti-CD4 mAb, was given at a dose of 20 mg/kg iv on days -3, -2, -1, and 0. hCTLA4-Ig was given at 6 mg/kg iv on days 0 and 2 for the first recipient, and days 0, 2, 4, and 6 for the second recipient. No further immunoBuppression was given. The treated (n=2) or untreated (n=5) recipients were followed for graft function by daily palpation. Treatment with anti-CD4-Ig plus hCTLA4-Ig resulted in a significant prolongation of heart graft survival (42 days for the first recipient and 52 days for the second recipient) compared to untreated recipients (7 days). FACS analysis demonstrated CD4 depletion of treated animals to

AB - The aim of this study was to determine whether the use of combined immunotherapy with a brief course of anti-CD4-Ig and hCTLA4-Ig would prolong heterotopic cardiac allograft survival in primates. This model was based on our previous study of ôhigh responderö rats where a brief course of depletive anti-CD4 mAb plus hCTLA4-Ig successfully induced tolerance. Heterotopic cardiac transplants were performed in MLR mismatched rhesus recipients. A recently developed humanized anti-CD4 mAb, was given at a dose of 20 mg/kg iv on days -3, -2, -1, and 0. hCTLA4-Ig was given at 6 mg/kg iv on days 0 and 2 for the first recipient, and days 0, 2, 4, and 6 for the second recipient. No further immunoBuppression was given. The treated (n=2) or untreated (n=5) recipients were followed for graft function by daily palpation. Treatment with anti-CD4-Ig plus hCTLA4-Ig resulted in a significant prolongation of heart graft survival (42 days for the first recipient and 52 days for the second recipient) compared to untreated recipients (7 days). FACS analysis demonstrated CD4 depletion of treated animals to

UR - http://www.scopus.com/inward/record.url?scp=33749278451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749278451&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749278451

VL - 12

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 5

ER -